Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Gait Parameters in Breast Cancer Receiving Chemotherapy Patients

NCT07894133 · tracked via the Priya Life Science Egypt tracker
Phase
Observational
Started
2026-10-01
Last updated
2026-10-26

Condition(s) studied

Breast CancerChemotherapyBiodex Gait TrainerGait Parameters

Investigational drug(s) / intervention(s)

Gait parameter assessment

Gait parameter assessment: A Biodex Gait Trainer 3 (BIODEX MEDICAL SYSTEMS, INC., New York, NY, model NO. 601-1-M90, EN 60601- 1 USA), is a device which is used to assess the spatiotemporal gait parameters of patients . It consists of a treadmill with an instrumented deck that monitors and records kinematic gait parameters including gait speed, step cycle, step length, and time on each foot (step symmetry). The patient will instructed to stand on the treadmill holding on handrails to ensure safety. Each patient will be asked to walk continuously for 3 minutes, till the evaluation session ended, and the gait trainer slow down gradually until it stopped. Three successive trials will be done for each patient. The mean value of each variable of spatiotemporal parameters of gait \[walking speed (meters per seconds), step cycle (cycle per second), step length (meter), and time on each foot (seconds)\] will be recorded.

Study summary

Breast cancer is considered the most common type of malignancies, it is the most frequently diagnosed representing around 2.3 million cases. Where, their chemotherapy may cause fatigue affecting the overall quality of patient's life. Gait and balance are fundamental for activities of daily living and maintaining functional independence.

Eligibility

Sex
FEMALE
Min age
40 Years
Max age
50 Years
Healthy volunteers
No
Inclusion Criteria: * Age ranged from 40 to 50 years old. * Female patients. * Suffering from breast cancer, and receiving chemotherapy. * Will be assessed before chemotherapy, 3 months and 6 months after chemotherapy. * All enrolled patients will have signed their informed consent signed. Exclusion Criteria: * No history of prior chemotherapy. * Current metastases. * Orthopedic problems that affect balance and gait. * Diabetic patients with neuritis. * Peripheral neuropathy. * Polyarthritis.

Primary outcome measure(s)

  • Walking Speed (Meter per second) — One time assessment throughout the study completion an average of 3 months.
    Walking Speed in unit of measurement is meter per second.
  • Step cycle (cycle per second) — One time assessment throughout the study completion an average of 3 months.
    Step cycle: in unit of measurement is Cycle per second.
  • Step length (Meter) — One time assessment throughout the study completion an average of 3 months.
    Step length in unit of measurement is meter.
  • Time on each foot (Seconds) — One time assessment throughout the study completion an average of 3 months.
    Time on each foot in unit of measurement is seconds

Trial sites (1)

FacilityCityRegionStatus
National Cancer Institute Cairo Cairo Governorate Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07894133 on ClinicalTrials.gov ↗ ← All trials in Egypt